NCT03184571

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: BerGenBio ASA · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib in combination with pembrolizumab in up to 106 participants with previously treated, advanced adenocarcinoma of the lung. The study will enrol three cohorts of participants with previously treated, advanced adenocarcinoma of the lung. Cohort A will consist of participants who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy. Cohort B will consist of participants who received a maximum of one prior line of an anti-programmed death receptor (PD)-(L)1 therapy (monotherapy). Cohort C will consist of participants who received a maximum of one prior line of therapy with an anti-PD-(L)1 therapy in combination with a platinum-containing chemotherapy. The primary objective is to assess the anti-tumor activity of bemcentinib in combination with pembrolizumab.

Conditions

• Lung Cancer Metastatic
• NSCLC Stage IV
• Adenocarcinoma of Lung

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Pembrolizumab is a PD-1 inhibitor
DRUG	Bemcentinib	Bemcentinib is a selective Axl kinase inhibitor;

Timeline

• Start date: 2017-10-02
• Primary completion: 2022-10-27
• Completion: 2022-10-27
• First posted: 2017-06-12
• Last updated: 2025-09-25
• Results posted: 2025-09-25

Locations

13 sites across 4 countries: United States, Norway, Spain, United Kingdom

Regulatory

• FDA-regulated drug study